These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24848052)

  • 41. The Children's Vaccine Initiative and vaccine supply: the role of the public sector.
    van Noort RB
    Vaccine; 1992; 10(13):909-10. PubMed ID: 1471410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Laboratories which produce veterinary vaccines.
    Randall DC
    Rev Sci Tech; 1998 Aug; 17(2):568-77. PubMed ID: 9713896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Research priorities for the WHO Global Programme for Vaccines and Immunization.
    Lambert PH
    Dev Biol Stand; 1996; 87():45-9. PubMed ID: 8854001
    [No Abstract]   [Full Text] [Related]  

  • 44. Vaccine storage and cold chain monitoring in the North West region of Cameroon: a cross sectional study.
    Yakum MN; Ateudjieu J; Walter EA; Watcho P
    BMC Res Notes; 2015 Apr; 8():145. PubMed ID: 25884186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. United Nations mercury treaty jeopardizes vaccine protection of the world's most vulnerable children.
    Durrheim DN; Poland GA
    Vaccine; 2013 Feb; 31(10):1357-8. PubMed ID: 23414666
    [No Abstract]   [Full Text] [Related]  

  • 47. The consistency approach for quality control of vaccines - a strategy to improve quality control and implement 3Rs.
    De Mattia F; Chapsal JM; Descamps J; Halder M; Jarrett N; Kross I; Mortiaux F; Ponsar C; Redhead K; McKelvie J; Hendriksen C
    Biologicals; 2011 Jan; 39(1):59-65. PubMed ID: 21277791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. One size does not fit all: The impact of primary vaccine container size on vaccine distribution and delivery.
    Haidari LA; Wahl B; Brown ST; Privor-Dumm L; Wallman-Stokes C; Gorham K; Connor DL; Wateska AR; Schreiber B; Dicko H; Jaillard P; Avella M; Lee BY
    Vaccine; 2015 Jun; 33(28):3242-7. PubMed ID: 25889160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.
    Nelson CM; Wibisono H; Purwanto H; Mansyur I; Moniaga V; Widjaya A
    Bull World Health Organ; 2004 Feb; 82(2):99-105. PubMed ID: 15042231
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Milestone and challenges: lessons from defective vaccine incidents in China.
    Fu C
    Hum Vaccin Immunother; 2020; 16(1):80. PubMed ID: 31339795
    [No Abstract]   [Full Text] [Related]  

  • 51. Chinese social media suggest decreased vaccine acceptance in China: An observational study on Weibo following the 2018 Changchun Changsheng vaccine incident.
    Hu D; Martin C; Dredze M; Broniatowski DA
    Vaccine; 2020 Mar; 38(13):2764-2770. PubMed ID: 32093982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Development and present status of a leptospiral vaccine and the technology of vaccine production in China].
    Chen T
    Nihon Saikingaku Zasshi; 1985 Jul; 40(4):755-62. PubMed ID: 3903244
    [No Abstract]   [Full Text] [Related]  

  • 53. Chinese vaccine developers gain WHO imprimatur.
    Jia H; Carey K
    Nat Biotechnol; 2011 Jun; 29(6):471-2. PubMed ID: 21654655
    [No Abstract]   [Full Text] [Related]  

  • 54. Global vaccine supply. The increasing role of manufacturers from middle income countries.
    Francis DP; Du YP; Precioso AR
    Vaccine; 2014 Sep; 32(41):5259-65. PubMed ID: 25110294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current situation and use of autogenous vaccines in France: the views of the manufacturer and the user.
    Thibault E
    Dev Biol (Basel); 2004; 117():73-81. PubMed ID: 15597620
    [No Abstract]   [Full Text] [Related]  

  • 56. Progress report on the National Immunization Strategy.
    Kondro W
    CMAJ; 2007 Jun; 176(13):1811-3. PubMed ID: 17576972
    [No Abstract]   [Full Text] [Related]  

  • 57. Assuring the quality and safety of vaccines: regulatory licensing and batch release.
    Griffiths E; Knezevic I
    Methods Mol Med; 2003; 87():353-76. PubMed ID: 12958467
    [No Abstract]   [Full Text] [Related]  

  • 58. Quality-control issues and approaches in vaccine development.
    Metz B; van den Dobbelsteen G; van Els C; van der Gun J; Levels L; van der Pol L; Rots N; Kersten G
    Expert Rev Vaccines; 2009 Feb; 8(2):227-38. PubMed ID: 19196202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reference standards for vaccine-producing laboratories.
    Castle P
    Rev Sci Tech; 1998 Aug; 17(2):585-91. PubMed ID: 9713898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Andhra Pradesh builds a model immunization system Indian state protects millions and shows what new vaccines and technologies can do.
    Cooley L
    Indian J Public Health; 2004; 48(2):67-9. PubMed ID: 15709588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.